<DOC>
	<DOCNO>NCT03083210</DOCNO>
	<brief_summary>Clinical data uncontrolled retrospective prospective study initially demonstrate antiproliferative effect lanreotide limit number patient lanreotide Autogel® recently approve 40 country treatment GEP-NET patient , base result CLARINET study , large prospective trial evaluate antiproliferative effect lanreotide Autogel® subject nonfunctional GEP-NETs . The study enrol 204 subject ( 101 subject randomize lanreotide Autogel® group 103 subject randomize placebo group , come 14 country ) well moderately differentiate non-functioning GEP-NETs , include pancreatic gastrointestinal tumor , define less 10 % proliferation marker Ki67 . The study show treatment lanreotide Autogel® significantly prolong progression-free survival subject GEP-NETs compare treatment placebo primary analysis ( median progression-free survival , reach vs. 18.0 month , P &lt; 0.001 stratified log-rank test ; hazard ratio progression death lanreotide vs. placebo , 0.47 ; 95 % confidence interval ( CI ) , 0.30 0.73 ) [ 5 ] . The indication GEP-NETs grant lanreotide Autogel® USA treatment patient unresectable , well moderately differentiate , locally advanced metastatic gastroenteropancreatic neuroendocrine tumor ( GEP-NETs ) improve progression-free survival ; European Union ( EU ) treatment grade 1 subset grade 2 ( Ki67 index 10 % ) gastroenteropancreatic neuroendocrine tumor midgut , pancreatic unknown origin hindgut sit origin exclude , adult patient unresectable locally advanced metastatic disease . The addition indication treatment patient GEP-NETs approve 15 authority include Canada , Australia Asian country , etc .</brief_summary>
	<brief_title>Study Lanreotide Metastatic Recurrent Grade I-II Hindgut NET</brief_title>
	<detailed_description>Patients advance hindgut NET n't receive prior systemic therapy receive laneotide . Study-arm compose 28 patient . Laneotide 120mg s.c. every 28 day .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histologically confirm well differentiate moderate differentiate neuroendocrine tumor . WHO 2010 Grade 1 2 Age &gt; 20 Measurable disease RECIST v 1.0 Primary tumor locate hindgut , colorectal area . Non function function NETs Unresectable locally advance metastatic disease Prior receive systemic therapy include interferon , chemotherapy , PRRT , chemoembolization somatostatin analogue time ( unless receive &gt; 6 month previously &lt; 15 day ) . Multiple endocrine neoplasia Previous cancer except case patient treat untreated situ cervical uterine carcinoma basal cell skin cancer patient cancer treat curative intent disease free &gt; 5 year Foregut , midgut , pancreatic NETs NETs unknown primary origin Cross reference : Hindgut : Distal 1/3rd transverse colon , descend colon , sigmoid colon , rectum , upper anal canal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>